JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mulder, K. M.
Right arrow Articles by Kostyniak, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mulder, K. M.
Right arrow Articles by Kostyniak, P. J.

Effect of L-(alpha S,5S)-alpha-amino-3-chloro-4,5-dihydro-5- isoxazoleacetic acid on urinary excretion of methylmercury in the mouse

KM Mulder and PJ Kostyniak

The gamma-GTP inhibitor L-(alpha S,5S)-alpha-amino-3-chloror-4,5- dihydro-5-isoxazoleacetic acid (AT-125) was administered to CBA/J mice pretreated with 203Hg-methylmercury (MM) (0.5 mg/kg) to determine whether increasing urinary GS in this strain would result in a simultaneously increased urinary elimination of MM. Doses at AT-125 ranging from 3.0 to 30 mg/kg increased urinary GS in a dose-related fashion. The peak effect was attained at 2 hr after injection. AT-125 (7.5 mg/kg) increased urinary GS to peak value of 450 microM. When this dose was administered to mice 24 hr after MM, neither the rate of decline in body burden of 203Hg nor the rate of 203Hg output into urine or feces varied significantly from control values. A dose of 15 mg of AT-125 per kg increased urinary GS to 1.0 mM and caused a significant increase in urinary excretion of 203Hg when compared to the 7.5-mg dose group. The greatest effect was seen at the 30-mg AT-125/kg dose which produced a 1.9 mM concentration of total GS in urine and a 2-fold increase in the urinary 203Hg excretion rate. The dose-dependent changes in urinary excretion elicited by AT-125 were paralleled by increased rates of decline of 203Hg body burden and decreased rates of excretion in the feces. The results suggest that urinary GS must approach the millimolar range before affecting a redistribution of MM across the luminal membrane.

Volume 234, Issue 1, pp. 156-160, 07/01/1985
Copyright © 1985 by American Society for Pharmacology and Experimental Therapeutics







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1985 by the American Society for Pharmacology and Experimental Therapeutics.